{"prompt": "['Alliance A221504', 'PATIENT INFORMATION SHEET', 'Patient Completed Booklet E', '(Every 3 months after the first year of treatment)', 'You have been given a booklet to complete for this study. This booklet contains some questions about', 'your \"quality-of-life\\' as a patient receiving treatment for cancer. Your answers will help us to better', 'understand how the treatment you are receiving is affecting the way you feel.', '1. After the first year of your study treatment, you are being asked to take this booklet home and', 'complete it every week. You should return the booklet when you return to the clinic every 3', 'months (month 15, month 18, month 21, etc.) after the first year of study treatment. It contains the', 'following questionnaire:', 'Pain and Pain Medication Diary', '2. Directions on how to complete each set of questions are written on the top of each set.', '3. It is very important that you return the booklets to us, whether you finish the study or not.', '4.', \"You will be given the nurse's or study coordinator's name and telephone number. You can call\", 'anytime with any concerns or questions.', '5. After completing this booklet, please return it to your nurse or physician or mail it back in the', 'provided envelope.', 'Thank you for taking the time to help us.', '96', 'Update 2', 'Version Date 6/25/2019']['Alliance A221504', 'APPENDIX VIII: HEMOLYZED PLASMA SAMPLES', 'Please note that hemolyzed plasma samples are NOT acceptable. Please re-draw if the samples are', 'hemolyzed. Below is a picture demonstrating different levels of hemolysis in plasma. Please be aware that', 'even mild hemolysis is not acceptable for this study plasma submission.', 'HI', '100', '200', '400', '800', '1600', '3200', 'Visual', 'Mild', 'Mod', 'Severe', '97', 'Update 2', 'Version Date 6/25/2019']['Alliance A221504', 'APPENDIX IX: NALOXEGOL WALLET CARD', '[Note to investigators: This convenient wallet-sized information card is to be completed and then', 'provided for the patient to clip out and retain at all times.]', 'INFORMATION ON POSSIBLE DRUG INTERACTIONS', 'Tell all of your prescribers (doctors, physician assistants,', 'You are enrolled on a clinical trial of naloxegol (Movantik\u00ae). This', 'nurse practitioners or pharmacists) that you are taking part in', 'clinicaltrialissponsored by the National Cancer institute (NCI).', 'a clinical trial.', 'Certain drugs may change the levels of liver enzymes such as', 'NAL', 'Before you enroll onto this clinical trial, your study doctor will', 'CYP3A4 which process or break down naloxegol in the body. In', 'work with your regular health care providers to review any', 'addition, naloxegol may change levels of CYP3A4 and this may', 'medicines and herbal supplements that are strong inducers', 'change how other medications are broken down. Because of this, it', 'or moderate/strong inhibitors of CYP3A4', 'is very important to:', 'Before prescribing new medicines, your regular prescribers', 'Tell your doctors if you stop taking regular medicine or if you', 'should go to', 'start taking a new medicine.', 'http://medicine.iupui.edu/clinpharm/ddis/table.aspx_for a', 'Check with your doctor or pharmacist whenever you need to', 'list of drugs to avoid, or contact your study doctor.', 'use an over-the-counter medicine or herbal supplement.', \"Your study doctor's name is\", 'and can be contacted at', '98', 'Update 2', 'Version Date 6/25/2019']\n\n###\n\n", "completion": "END"}